Clinical trials in minimal change disease

Area of Science:

• Nephrology
• Immunology
• Pharmacology

Background:

• Minimal change disease (MCD) is a primary cause of nephrotic syndrome, characterized by reversible proteinuria but often relapsing.
• Steroid resistance or toxicity necessitates alternative treatments for sustained remission.
• Unresolved MCD can progress to focal and segmental glomerulosclerosis (FSGS), a more severe kidney disease.

Purpose of the Study:

• To review current and emerging therapeutic strategies for Minimal Change Disease (MCD).
• To highlight the impact of new interventions on understanding MCD pathogenesis.
• To discuss ongoing clinical trials for novel MCD treatments and potential FSGS therapies.

Main Methods:

• Review of historical and current treatments for MCD.
• Analysis of ongoing Phase II-IV clinical trials targeting novel mechanisms and molecules.
• Exploration of drugs affecting adaptive immunity, glomerular basement membrane properties, and potential FSGS treatments.

Main Results:

• Traditional immunosuppressants like cyclophosphamide and calcineurin inhibitors have shown success but carry toxicity risks.
• Emerging therapies include synthetic corticotropin, anti-CD20 monoclonal antibodies, abatacept, anti-CD40 antibodies, retinoids, and N-acetyl-D-mannosamine (ManNAc).
• Clinical trials are actively investigating these novel agents, offering hope for improved MCD management.

Conclusions:

• New therapeutic avenues are significantly advancing MCD treatment and understanding.
• Targeting adaptive immunity and glomerular basement membrane function are key strategies.
• Ongoing clinical trials are expected to provide definitive solutions for managing MCD and preventing FSGS progression.